Isotope analysis is moving beyond specialised laboratories towards broader, molecular-level applications. In this BioSpe...
China’s biotech and pharmaceutical sector is entering a new phase of global relevance. A surge in out-licensing de...
How is Takeda’s partnership with Biological E. Limited playing a role in strengthening dengue vaccine access in In...
As cell therapies advance towards greater clinical sophistication and commercial scale, the focus is shifting fr...
In conversation with BioSpectrum Asia, Laurie Masiello and John Masiello, Co-Founders of Predictive Monitor, explore how...
Australia is rapidly evolving beyond its reputation as a destination for early-stage clinical trials to build a more com...
How are Australia–India health partnerships driving innovations in the non-communicable diseases sector? We have ...
For decades, cancer treatment has largely focused on finding a single breakthrough therapy capable o...
J-Pharma has built its pipeline around amino acid transporter (LAT1)-targeted therapies. What was the vision behind this...
RESILIA tissue has been positioned as a significant advancement in valve technology. How does RESILIA tissue differ from...
Asia's biopharmaceutical manufacturing sector is entering a new phase of growth, driven by expanding biologics pipelines...
Africa carries the majority of the global sickle cell disease burden, yet care across many health systems remains fragme...
The next generation of cell and gene therapies is pushing manufacturing beyond the limits of conventiona...
Exosomes are rapidly emerging as one of the most promising frontiers in regenerative medicine, offering the therapeutic ...
As BIO Asia–Taiwan 2026 brought the region’s biotechnology and healthcare ecosystem together in Taip...
Drug development is approaching a significant inflection point. Advances in induced pluripotent stem cells (iPSCs), orga...
Cell therapy is approaching a defining transition: from highly specialised science to a reproducible, scalable pharmaceu...
The pharmaceutical industry’s innovation equation is changing. Developing an entirely new molecu...
The global CDMO market is moving beyond the era when manufacturing capacity alone defined competitive ...
As BioSpectrum Asia reports on the ground from BIO Asia–Taiwan 2026, being held from July 15–19 in T...
As gene therapy moves from scientific promise towards a new phase of commercial maturity, manufacturing has emerged as o...
Advancing Clinical Development and Evidence Generation Clinical development is entering a new era where success depends...
As cell and gene therapies progress from promising research to commercial reality, manufacturing has emerged as ...
As antibody-drug conjugates (ADCs) transition from a promising therapeutic modality to a cornerstone of precision oncolo...
As antibody-drug conjugates (ADCs), bispecific antibodies and other advanced biologics redefine the global therapeutics ...
